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Association of a rare variant of the 
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to Rheumatoid Arthritis and 
Systemic Lupus Erythematosus
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A rare variant (BAFF-var) of the tumor necrosis factor superfamily 13b (TNFSF13B) gene has been 
recently associated with multiple sclerosis (MS) and systemic lupus erythematosus (SLE). The aim of this 
study was to investigate the association between TNFSF13B BAFF-var and susceptibility to rheumatoid 
arthritis (RA) and replicate that association in SLE. 6,218 RA patients, 2,575 SLE patients and 4,403 
healthy controls from three different countries were included in the study. TNFSF13B BAFF-var was 
genotyped using TaqMan allelic discrimination assay. PLINK software was used for statistical analyses. 
TNFSF13B BAFF-var was significantly associated with RA (p = 0.015, OR = 1.21, 95% CI = 1.03–1.41) in 
the Spanish cohort. A trend of association was observed in the Dutch (p = 0.115) and German (p = 0.228) 
RA cohorts. A meta-analysis of the three RA cohorts included in this study revealed a statistically 
significant association (p = 0.002, OR = 1.24, 95% CI = 1.10–1.38). In addition, TNFSF13B BAFF-var 
was significantly associated with SLE in the Spanish (p = 0.001, OR = 1.41, 95% CI = 1.14–1.74) and 
the German cohorts (p = 0.030, OR = 1.86, 95% CI = 1.05–3.28), with a statistically significant p-value 
obtained in the meta-analysis (p = 0.0002, OR = 1.46, 95% CI = 1.09–2.32). The results obtained confirm 
the known association of TNFSF13B BAFF-var with SLE and, for the first time, demonstrate that this 
variant contributes to susceptibility to RA.
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Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are complex autoimmune diseases influenced 
by both genetic and environmental factors1,2. Genome-wide association studies (GWAS) have revealed more 
than 100 independent signals for RA and 50 for SLE associated with these diseases3,4. In a recent study Steri et al.5  
identified an association signal in the TNFSF13B gene which was associated with multiple sclerosis (MS) and 
SLE. TNFSF13B encodes tumor necrosis factor superfamily member 13b (also known as B-cell activating factor 
(BAFF)). BAFF is a cytokine that is primarily produced by monocytes and neutrophils and plays a crucial role 
in B-cell homeostasis and the regulation of B-cell maturation, differentiation and survival6. This cytokine plays a 
particularly important role in the pathogenesis of SLE, to such an extent that the first targeted therapy approved 
for SLE was Belimumab, a monoclonal antibody targeting human BAFF7–9. The causal variant identified by Steri 
et al.5 for this association, “BAFF-var”, is an insertion-deletion in which five nucleotides are replaced by one 
(GCTGT > A), being this A the risk allele. Persons carrying the A allele have an increased risk for the disease. 
This risk allele results in a shorter transcript that escapes microRNA inhibition thus leading to an increase in 
the production of soluble BAFF. Besides, it has been observed that TNFSF13B BAFF-var is strongly associated 
with augmented levels of total IgG and IgM and with reduced monocyte counts5. Thus, TNFSF13B BAFF-var is 
considered a shared genetic risk variant for autoimmune diseases based on its association with MS and SLE, and 
it plays an important role in autoimmune processes5. Considering that replication of previous results is of vital 
importance for the correct development of scientific knowledge, we performed a replication study to corroborate 
the association of TNFSF13B BAFF-var with susceptibility to SLE.
Otherwise, BAFF system dysregulation is involved in the pathogenesis of RA1,10 and abnormal levels of BAFF 
have been detected in serum, synovial fluid and saliva from RA patients11. It is noteworthy that more than 10 
shared risk loci have been identified for SLE and RA12,13. Taking into considerations above, we aimed to assess for 
the first time the potential association of TNFSF13B BAFF-var with RA in patients from Spain, the Netherlands 
and Germany.
Materials and Methods
Study subjects. Overall, 6,218 RA patients and 4,403 healthy controls from Spain, Germany and the 
Netherlands were enrolled in our study. Regarding the Spanish cohort, DNA was obtained from 4,429 RA patients 
from the Xeral-Calde University Hospital, Lugo; Marqués de Valdecilla University Hospital, Santander; Bellvitge 
University Hospital, Barcelona; Virgen del Rocío University Hospital, Seville; Campus de la Salud University 
Hospital, Granada; and Hospital Clínico San Carlos, La Princesa University Hospital, La Paz University Hospital, 
12 de Octubre University Hospital and Gregorio Marañon University Hospital, all located in Madrid. DNA from 
3,200 healthy controls was obtained from Banco Nacional de ADN. DNA was obtained from 890 RA patients 
and 733 controls from the Netherlands at the Radboud University Medical Center (Nijmegen) and the Nijmegen 
Biomedical Study (NBS)14 respectively. DNA was obtained from 890 RA patients and 470 controls of German 
descent at the Hannover Medical School (Hannover) and Düsseldorf University Hospital. All the patients 
included in this study were of European descent and had been diagnosed with RA according to the 1987 classifi-
cation criteria of the American College of Rheumatology15.
A total of 2,575 SLE patients from Spain and Germany were included in this study. DNA from 1,160 patients 
from Spain was obtained at Xeral-Calde University Hospital, Lugo; Virgen del Rocío University Hospital, 
Sevilla; Virgen de las Nieves University Hospital, Granada; Virgen de la Victoria University Hospital, Málaga, 
and Parc Taulí University Hospital, Sabadell. DNA from 460 German patients was obtained at the Hannover 
Medical School, Hannover. All SLE patients were of European descent and fulfilled the American College of 
Rheumatology criteria for the classification of SLE16.
The study was approved by the local ethical committees of the different participating centers (Ethics 
Committee of the Spanish National Research Council, Xeral-Calde University Hospital, Marqués de Valdecilla 
University Hospital, Bellvitge University Hospital, Virgen del Rocío University Hospital, Campus de la Salud 
University Hospital, Hospital Clínico San Carlos, La Princesa University Hospital, La Paz University Hospital, 
12 de Octubre University Hospital and Gregorio Marañon University Hospital, Virgen de las Nieves University 
Hospital, Virgen de la Victoria University Hospital, Parc Taulí University Hospital, Radboud University Medical 
Center, Hannover Medical School and Düsseldorf University Hospital) in accordance with the tenets of the 
Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrolment in the 
study.
Genotyping. Genomic DNA was isolated from peripheral blood samples using standard salting-out tech-
niques. TNFSF13B BAFF-var was genotyped using a TaqMan allelic discrimination custom assay (assay ID: 
AH0JGPG) (Applied Biosystems, Foster City, California, USA) on an ABI 7900HT Fast Real-Time PCR System 
(Thermo Fisher). Genotyping call rate was >95% in all sample sets.
Statistical analysis. All the statistical analyses were carried out with PLINK v1.9 (http://pngu.mgh.harvard.
edu/purcell/plink/)17. For all groups of individuals, Hardy-Weinberg equilibrium was determined at a significance 
level of 0.01. Differences between allele and genotype frequencies in individuals were determined by χ2 test. Odds 
ratios (ORs) and 95% confidence intervals were calculated according to Woolf ’s method. Meta-analyses were 
performed with inverse-variance method under a fixed-effects model. Heterogeneity of the ORs across cohorts 
was assessed using both Cochran’s Q test and inconsistency index (I2). The statistical power of our study was 
calculated by using Power Calculator for Genetic Studies 2006 (CaTS) software (http://www.sph.umich.edu/csg/
abecasis/CaTS/)18, under an additive model. The statistical power of the study for determining significance at a p 
value of 0.05 is shown in Supplementary Table S1.
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Data availability. The complete datasets generated and analyzed during the current study are available from 
the corresponding author on reasonable request.
Ethical use of human participants statement. All participants signed a written informed consent 
prior to their enrolment in the study for identified data to be published. All procedures were performed after 
signed informed consent was obtained from patients and in accordance with the local (Spanish National Research 
Council) ethics committee and the Declaration of Helsinki of 1975, as revised in 1983.
Results
First, in order to evaluate the association between the TNFSF13B gene variant (BAFF-var) and susceptibility to 
RA, a comparative analysis of allelic and genotype frequencies in RA patients vs. healthy individuals was per-
formed in the Spanish, Dutch and German populations. Results are shown in Table 1. The minor allele frequency 
(A) of TNFSF13B BAFF-var was higher in RA patients in the three populations included in this study. This differ-
ence was statistically significant in the Spanish subgroup (p = 0.015, OR = 1.21, 95% CI = 1.03–1.41), and sugges-
tive associations were observed in the Dutch (p = 0.115, OR = 1.47, 95% CI = 0.91–2.36) and German (p = 0.228, 
OR = 1.39, 95% CI = 0.81–2.36) subgroups. In addition, a statistically significant p value was obtained in the 
meta-analysis of the three RA populations included in this study (p = 0.002, OR = 1.24, 95% CI = 1.10–1.38) with 
low heterogeneity levels (heterogeneity q value = 0.64, I2 = 0) (Table 1).
Secondly, to try to replicate the results previously published by Steri et al.5, a comparative analysis of allelic and 
genotype frequencies in SLE patients vs. healthy individuals from the Spanish and German populations was also 
performed (Table 2). The minor allele frequency (A) in TNFSF13B BAFF-var was statistically significantly higher 
in SLE patients than in controls in both, the Spanish (p = 0.0001, OR = 1.41, 95% CI = 1.14–1.74) and German 
(p = 0.030, OR = 1.86, 95% CI = 1.05–3.28) subgroups. Meta-analysis of the two SLE populations included in this 
study revealed a statistically significant p value (p = 0.0002, OR = 1.46, 95% CI = 1.09–2.32) with low heterogene-
ity levels (heterogeneity q value = 0.37, I2 = 0) (Table 2).
Discussion
We confirm the recently reported association of the TNFSF13B BAFF-var with SLE in two independent popula-
tions of Spanish and German origin. In addition, this is the first time that evidence is provided of an association 
between TNFSF13B BAFF-var and RA. These findings, together with the data reported by Steri et al.5, suggest that 
TNFSF13B BAFF-var is a common genetic risk factor for autoimmunity.
SLE and RA mice models showed increased serum BAFF levels, and BAFF blockade reduced diseases man-
ifestations19,20. Nevertheless, although clinical trials are being performed on BAFF in RA and SLE patients, only 
moderate results are emerging. An example of these modest results is the BAFF-inhibitor drug belimumab, which 
has been found to be only moderately effective in a small number of patients with RA and SLE8,21. Because RA and 
SLE are heterogeneous diseases with different biological subsets, the efficacy of different drugs could be divergent 
in specific patient subgroups. Therefore, our new findings could help in the advance of RA therapies, as patients 
stratified by TNFSF13B BAFF-var status may show a differential benefit from anti-BAFF therapies. In this sense, a 
recent study showed that a TNFSF13B genetic variant influenced response to B-cell targeted therapy (rituximab) 
in patients with RA22. Furthermore, B-cell-depleting therapies in patients carrying TNFSF13B BAFF-var would 
have a weaker effect due to a rapid resurgence of memory B cells induced by high soluble BAFF levels, which 
could increase the risk of inadequate response and/or relapse23.
Genome-wide association studies (GWAS) have identified multiple risk genetic factors associated with human 
autoimmune disease. Of note, GWAS are designed to detect only common genetic variants (>5%); however, 
low-frequency and rare variants may represent an important component of autoimmune risk and provide a key 
Subgroup (N)
Genotype (N)
MAF (%)
Allele test
A|A A|GCTGT GCTGT|GCTGT P-value OR [95% CI]a
Spain
Controls (3,200)b 10 249 2941 4.20
RA (4,429) 11 424 3994 5.03 0.015 1.21 [1.03–1.41]
Netherlands
Controls (733) 0 28 705 1.91
RA (890) 0 49 841 2.75 0.115 1.47 [0.91–2.36]
Germany
Controls (470)b 0 19 451 2.02
RA (899) 3 44 852 2.78 0.228 1.39 [0.81–2.36]
Meta-analysisc
Controls (4,403)
RA (6,218) 0.002 1.24 [1.10–1.38]
Table 1. Association analysis of the TNFSF13B BAFF-var in three independent RA cohorts and meta-analysis. 
Abbreviations: N: Number of individuals; MAF: Minor Allele Frequency; OR: Odds Ratio; CI: Confidence 
Interval. aOR for the minor allele. bHealthy controls were used as reference for RA and SLE patients in Spanish 
and German subgroups. cHeterogeneity q value = 0.64, I2 = 0.
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insight into both novel and previously implicated immunological pathways that are disrupted in autoimmune 
diseases24. Thus, large genetic studies have identified low frequency variants with relevant functional significance 
associated with autoimmune diseases (e.g. TREX1 in SLE25 and TYK2 in several autoimmune diseases26,27). Our 
findings support the important role of rare variants, such as TNFSF13B BAFF-var, in understanding the unknown 
mechanisms of autoimmunity.
For the first time, our results showed that allele A of TNFSF13B BAFF-var was associated with the risk of 
RA in the Spanish population. Trends of association were observed in the Dutch and German RA cohorts. This 
could be due to a low statistical power as the Dutch and the German cohorts sample sizes are relatively small as 
compared to the Spanish cohort, as well as the minor allele frequency is less common in northern Europe (2.02% 
in Germany and 1.91% in the Netherlands) than in southern Europe (4.2% in Spain). This north-south gradient 
in the minor allele frequency of TNFSF13B BAFF-var has been previously reported, with higher frequencies 
observed in southern Europe (5.7% in Italy and 4.9% in Spain) than in northern Europe (1.8% in United Kingdom 
and Sweden)5. However, the three RA cohorts showed higher levels of allele A in cases than in controls and sta-
tistically significant association was observed in the meta-analysis. Thus, further studies involving larger cohorts 
would be necessary to elucidate if this variant is associated with autoimmune risk in northern populations.
Regarding the SLE replication study, our results confirm the association of allele A of TNFSF13B BAFF-var 
with the risk of SLE in the Spanish and German populations. The association of the variant was found to be 
stronger in SLE than in RA and, in both cases, the allele A acts as a risk factor.
GWAS have revealed a significant shared genetic component in autoimmunity28,29. The association of 
TNFSF13B BAFF-var with RA and SLE observed in our study extends the number of overlapping genetic risk 
factors across different autoimmune diseases. In this regard, performing further studies to elucidate the specific 
association of TNFSF13B BAFF-var with other autoimmune diseases would be of great interest as new therapy 
approaches involving BAFF could emerge.
In conclusion, our results suggest that TNFSF13B BAFF-var plays an important role in susceptibility to RA, 
and confirm the association of this variant with SLE.
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